Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

被引：1
|
作者：
Chica-Parrado, Maria del Rosario
Kin, Gun Min
Lin, Chang-Ching
Lee, Kyung-Min
Napolitano, Fabiana
Ye, Dan
Bikorimana, Emmanuel
Mendirata, Saurabh
Hanker, Ariella
Arteaga, Carlos L.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5483
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5483
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)
    Chica-Parrado, Rosario
    Kim, Gun Min
    Uemoto, Yasuaki
    Ye, Dan
    Napolitano, Fabiana
    Lin, Chang-Ching
    Bikorimana, Emmanuel
    Lee, Kyung-Min
    Mendiratta, Saurabh
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer
    Chica-Parrado, Maria Rosario
    Kim, Gun Min
    Uemoto, Yasuaki
    Napolitano, Fabiana
    Lin, Chang-Ching
    Ye, Dan
    Bikorimana, Emmanuel
    Fang, Yisheng
    Lee, Kyung-min
    Mendiratta, Saurabh
    Hanker, Ariella B.
    Arteaga, Carlos L.
    CANCER LETTERS, 2024, 604
  • [3] Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype
    Kim, Gun Min
    Lee, Kyung-min
    Sudhan, Dhivya
    Lin, Albert
    Marin, Arnaldo
    Chatterjee, Sumanta
    Ye, Dan
    Kandagatla, Vishal
    Mendiratta, Saurabh
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition.
    Asghar, Uzma
    Herrera-Abreu, Maria Teresa
    Cutts, Ros
    Babina, Irina
    Pearson, Alex
    Turner, Nicholas C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Characteristics, outcomes and prognostic factors of luminal androgen receptor (LAR) triple-negative breast cancer (TNBC)
    Leon-Ferre, R. A.
    Polley, M-Y
    Liu, H.
    Kalari, K. R.
    Boughey, J. C.
    Liu, M. C.
    Cafourek, V.
    Negron, V.
    Ingle, J. N.
    Thompson, K. J.
    Tang, X.
    Barman, P.
    Carlson, E.
    Visscher, D. W.
    Carter, J. C.
    Couch, F. J.
    Goetz, M. P.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] CDK4/6 inhibition in luminal breast cancer
    Gampenrieder S.P.
    Rinnerthaler G.
    Greil R.
    memo - Magazine of European Medical Oncology, 2016, 9 (2) : 76 - 81
  • [7] Investigating CDK4/6 inhibition in triple negative breast cancer
    Guo, Qiuchen
    Goreczny, Gregory J.
    Spasic, Milos
    Maynard, Adam
    McAllister, Sandra S.
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features
    Vtorushin, Sergey
    Dulesova, Anastasia
    Krakhmal, Nadezhda
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2022, 23 (08): : 617 - 624
  • [9] Triple-negative Breast Cancer (TNBC) and Its Luminal Androgen Receptor (LAR) Subtype: A Clinicopathologic Review of Cases in a University Hospital in Northwestern Nigeria
    Liman, A. A.
    Kabir, B.
    Abubakar, M.
    Abdullahi, S.
    Ahmed, S. A.
    Shehu, S. M.
    NIGERIAN JOURNAL OF CLINICAL PRACTICE, 2022, 25 (01) : 97 - 104
  • [10] CDK4/6 inhibition in early stage triple negative breast cancer
    Kietzman, William B.
    Ory, Virginie
    Saenz, Fransisco
    Sharif, Ghada
    Wellstein, Anton
    Riegel, Anna T.
    CANCER RESEARCH, 2017, 77
12345